Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile
March 17, 2017 07:00 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., March 17, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a two-year contract with the Biomedical Advanced Research and...
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals
February 23, 2017 16:15 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2016. 2016 FINANCIAL...
Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics
February 13, 2017 07:00 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received a task order from the Biomedical Advanced Research and Development...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a Conference Call on February 23, 2017
February 09, 2017 07:00 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 23, 2017 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue
February 01, 2017 07:00 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b multiple ascending dose study to evaluate the safety and...
Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax
January 27, 2017 07:00 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Jan. 27, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal...
Emergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlook
January 09, 2017 07:00 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced preliminary unaudited 2016 financial results and guidance for 2017. Daniel J. Abdun-Nabi,...
Emergent BioSolutions to Participate in First Quarter 2017 Investor Conferences
December 29, 2016 16:15 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following...
Emergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin
December 12, 2016 07:00 ET
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its...
Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile
December 08, 2016 17:12 ET
|
Emergent BioSolutions Inc.
Company signs follow-on contract with CDC valued at up to $911 million to supply to the SNS approximately 29.4 million doses of BioThrax through September 2021BARDA issues notice of intent to...